Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The threshold-suspend feature of sensor-augmented insulin pumps is designed to minimize the risk of hypoglycemia by interrupting insulin delivery at a preset sensor glucose value. We evaluated sensor-augmented insulin-pump therapy with and without the threshold-suspend feature in patients with nocturnal hypoglycemia. METHODS: We randomly assigned patients with type 1 diabetes and documented nocturnal hypoglycemia to receive sensor-augmented insulin-pump therapy with or without the threshold-suspend feature for 3 months. The primary safety outcome was the change in the glycated hemoglobin level. The primary efficacy outcome was the area under the curve (AUC) for nocturnal hypoglycemic events. Two-hour threshold-suspend events were analyzed with respect to subsequent sensor glucose values. RESULTS: A total of 247 patients were randomly assigned to receive sensor-augmented insulin-pump therapy with the threshold-suspend feature (threshold-suspend group, 121 patients) or standard sensor-augmented insulin-pump therapy (control group, 126 patients). The changes in glycated hemoglobin values were similar in the two groups. The mean AUC for nocturnal hypoglycemic events was 37.5% lower in the threshold-suspend group than in the control group (980 ± 1200 mg per deciliter [54.4 ± 66.6 mmol per liter] × minutes vs. 1568 ± 1995 mg per deciliter [87.0 ± 110.7 mmol per liter] × minutes, P<0.001). Nocturnal hypoglycemic events occurred 31.8% less frequently in the threshold-suspend group than in the control group (1.5 ± 1.0 vs. 2.2 ± 1.3 per patient-week, P<0.001). The percentages of nocturnal sensor glucose values of less than 50 mg per deciliter (2.8 mmol per liter), 50 to less than 60 mg per deciliter (3.3 mmol per liter), and 60 to less than 70 mg per deciliter (3.9 mmol per liter) were significantly reduced in the threshold-suspend group (P<0.001 for each range). After 1438 instances at night in which the pump was stopped for 2 hours, the mean sensor glucose value was 92.6 ± 40.7 mg per deciliter (5.1 ± 2.3 mmol per liter). Four patients (all in the control group) had a severe hypoglycemic event; no patients had diabetic ketoacidosis. CONCLUSIONS: This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced nocturnal hypoglycemia, without increasing glycated hemoglobin values. (Funded by Medtronic MiniMed; ASPIRE ClinicalTrials.gov number, NCT01497938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“People with diabetes who continue to have frequent and severe hypoglycemia and/or impaired awareness of hypoglycemia, despite educational interventions, may benefit from continuous subcutaneous insulin infusion (CSII) therapy or continuous glucose monitoring (CGM) or both (i.e. a sensor augmented pump), to reduce the risk of severe hypoglycemia (44)(45)(46)(47).”
From Hypoglycemia (2018) · cites this paper as [46]
In the citing paper
“Insulin pumps with automated low-glucose suspend and automated insulin delivery systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (126).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [126]
In the citing paper
“Reduction of nocturnal hypoglycemia in individuals with type 1 diabetes using insulin pumps with CGM is improved by automatic suspension of insulin delivery at a preset glucose level, with further improvements when using devices with predictive low-glucose insulin delivery suspension (24,25).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [24]
In the citing paper
“CGM with automated low glucose suspend and hybrid closed-loop systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (95).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [95]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Self-citationHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Fear of hypoglycemia: quantification, validation, and utilization
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, J. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.617 · Cited by 579
Mechanisms of Hypoglycemia-Associated Autonomic Failure and Its Component Syndromes in Diabetes
Cryer, P. E. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3592 · Cited by 401
Adaptive increase in sample size when interim results are promising: a practical guide with examples
Mehta, C. R., & Pocock, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4102 · Cited by 367
Towler, D. A., Havlin, C. E., Craft, S., & Cryer, P. (1993) · Diabetes · doi:10.2337/diab.42.12.1791 · Cited by 258
Tanenberg, R. J., Newton, C. A., & Drake, A. J. (2010) · Endocrine Practice · doi:10.4158/ep09260.cr · Cited by 225
Increasing the sample size when the unblinded interim result is promising
Chen, Y. H. J., DeMets, D. L., & Gordon Lan, K. K. (2004) · Statistics in Medicine · doi:10.1002/sim.1688 · Cited by 207
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Cited by
Items 101–200 of 662
Bosi, E., Choudhary, P., de Valk, H. W., Lablanche, S., Castañeda, J., de Portu, S., Silva, J. D., Ré, R., Vorrink, L., Shin, J., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30150-0 · Cited by 130
Self-citationPettus, J., & Edelman, S. V. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816663747 · Cited by 131
“The clinical benefits of real-time continuous glucose monitoring (rtCGM) use have been well demonstrated in both CSII- and MDI-treated T1D individuals; however, few studies have specifically looked at how individuals utilize rtCGM data.1,2 Although CGM management algorithms were established for subjects in clinical tr…”
BackgroundInfluentialChoudhary, P., Olsen, B. S., Conget, I., Welsh, J. B., Vorrink, L., & Shin, J. J. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0324 · Cited by 118
Self-citationMcAuley, S. A., Trawley, S., Vogrin, S., Ward, G. M., Fourlanos, S., Grills, C. A., Lee, M. H., Alipoor, A. M., O’Neal, D. N., O’Regan, N. A., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1667 · Cited by 117
Role of continuous glucose monitoring for type 2 in diabetes management and research
Vigersky, R. A., & Shrivastav, M. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.007 · Cited by 126
Pathway to Artificial Pancreas Systems Revisited: Moving Downstream
Kowalski, A. J. (2015) · Diabetes Care · doi:10.2337/dc15-0364 · Cited by 126
Biester, T., Berget, C., Boughton, C. K., Cudizio, L., Ekhlaspour, L., Hilliard, M. E., Reddy, L., Sap, S. N. U., Schoelwer, M. J., Sherr, J. L., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543034 · Cited by 124
“They were signi fi cantly reduced with the use of the LGS system without any deterioration in glycemia as measured by HbA1c [170, 171].”
Wearable, Sensing-Controlled, Ultrasound-Based Microneedle Smart System for Diabetes Management
Luo, X., Yu, Q., Yang, L., & Cui, Y. (2023) · ACS Sensors · doi:10.1021/acssensors.2c02863 · Cited by 116
Toward a Run-to-Run Adaptive Artificial Pancreas: In Silico Results
Toffanin, C., VISENTIN, R., Messori, M., Palma, F. D., Magni, L., & Cobelli, C. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2017.2652062 · Cited by 123
“A comprehensive review of the early developments in the AP field and of the first inpatient closed-loop control studies can be found in [1], and several recent reviews highlight additional progresses in this field [2]–[4].”
BackgroundCurrent Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
Moon, S. J., Jung, I., & Park, C.-Y. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0177 · Cited by 98
“2013 [16] Medtronic Medtronic Enlite Minimed 530G Minimed 530G RCT, parallel 247 16–70 Home 3 months LGS SAP SAP Nocturnal hypoglycemic events: 1.”
BackgroundDiabetes in Childhood and Adolescence
Ziegler, R., & Neu, A. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0146 · Cited by 147
Abraham, M. B., Karges, B., Dovč, K., Naranjo, D. M., Arbeláez, A. M., Mbogo, J., Javelikar, G., Jones, T. W., & Mahmud, F. H. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13443 · Cited by 135
Is an artificial pancreas (closed‐loop system) for Type 1 diabetes effective?
Boughton, C. K., & Hovorka, R. (2018) · Diabetic Medicine · doi:10.1111/dme.13816 · Cited by 118
Accuracy and Acceptability of the 6-Day Enlite Continuous Subcutaneous Glucose Sensor
Bailey, T. S., Ahmann, A., Brazg, R., Christiansen, M. P., Garg, S. K., Watkins, E., Welsh, J. B., & Lee, S. W. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0222 · Cited by 106
Self-citationJohnson, M. L., Martens, T. W., Criego, A. B., Carlson, A. L., Simonson, G. D., & Bergenstal, R. M. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0034 · Cited by 104
Self-citationYale, J.-F., Paty, B., & Senior, P. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.010 · Cited by 105
Georga, E. I., Protopappas, V. C., Polyzos, D. K., & Fotiadis, D. I. (2015) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-015-1263-1 · Cited by 110
Flash Glucose Monitoring Improves Outcomes in a Type 1 Diabetes Clinic
Dover, A. R., Stimson, R. H., Zammitt, N. N., & Gibb, F. W. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816661560 · Cited by 113
“FGM is also considerably cheaper than conventional CGM(1) but lacks alarm features and connectivity with continuous subcutaneous insulin infusion (CSII) devices, such as low-glucose suspend.(2) The accuracy and usability of FGM have been validated in patients with both type 1 and type 2 diabetes.”
BackgroundRealizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes
Lal, R., Ekhlaspour, L., Hood, K. K., & Buckingham, B. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00174 · Cited by 116
Diabetes Self-Care and the Older Adult
Weinger, K., Beverly, E. A., & Smaldone, A. M. (2014) · Western Journal of Nursing Research · doi:10.1177/0193945914521696 · Cited by 113
“A more recent technological innovation, the sensor-augmented insulin pumps programmed to interrupt insulin delivery at a preset glucose value, have been found to further improve safety (Bergenstal et al., 2013).”
BackgroundTechnology in the management of type 2 diabetes: Present status and future prospects
DALY, A. B., & Hovorka, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14418 · Cited by 107
The Artificial Pancreas and Type 1 Diabetes
Nwokolo, M., & Hovorka, R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad068 · Cited by 119
“…monitoring enabled the development of low-glucose suspend (automated insulin infusion suspension at a set low glucose threshold) and predictive low-glucose suspend pump therapy (insulin infusion suspension in anticipation of an algorithm-predicted low and restart once glucose in target) (5, 6).”
BackgroundTime in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control
Yoo, J. H., & Kim, J. H. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0257 · Cited by 107
HYPOS-1 Study Group of AMD, Giorda, C. B., Ozzello, A., Gentile, S., Aglialoro, A., Chiambretti, A., Baccetti, F., Gentile, F. M., Lucisano, G., Nicolucci, A., et al. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0713-4 · Cited by 97
Continuous Glucose Monitoring, Future Products, and Update on Worldwide Artificial Pancreas Projects
Kropff, J., & DeVries, J. H. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0345 · Cited by 109
“Two randomized controlled trials were performed investigating low glucose suspend (LGS) (Medtronic, Northridge, CA), Bergenstal et al. 23 showed reduced incidence and duration of nonsevere hypoglycemia, whereas Ly et al. 24 showed reduced incidence and duration of nonsevere and severe hypoglycemia…”
The Artificial Pancreas in 2016: A Digital Treatment Ecosystem for Diabetes
Kovatchev, B., Tamborlane, W. V., Cefalu, W. T., & Cobelli, C. (2016) · Diabetes Care · doi:10.2337/dc16-0824 · Cited by 95
Sharifi, A., de Bock, M. I., Jayawardene, D., Loh, M., Horsburgh, J. C., Berthold, C. L., Paramalingam, N., Bach, L. A., Colman, P. G., Davis, E. A., et al. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0288 · Cited by 98
“10,11 However, while suspension of insulin delivery reduces hypoglycemia, it does not directly address elevated glucose levels.”
Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes
Haidar, A., RABASA-LHORET, R. P. R., Legault, L., Lovblom, L. E., Rakheja, R., Messier, V., D'Aoust, É., Falappa, C. M., Justice, T. D., Orszag, A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3003 · Cited by 99
Managing diabetes in preschool children
Sundberg, F., Barnard, K., Cato, A., de Beaufort, C., DiMeglio, L. A., Dooley, G., Hershey, T., Hitchcock, J., Jain, V., Weissberg-Benchell, J., et al. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12554 · Cited by 91
Danne, T., Tsioli, C., Kordonouri, O., Bläsig, S., Remus, K., Roy, A., Keenan, D. B., Lee, S. W., & KAUFMAN, F. R. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0327 · Cited by 93
Self-citationDiagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T., Karges, B., Kordonouri, O., et al. (2016) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-111213 · Cited by 91
Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy
Fuchs, J., & Hovorka, R. (2020) · Expert Review of Medical Devices · doi:10.1080/17434440.2020.1784724 · Cited by 104
Insulin Therapy in Children and Adolescents with Type 1 Diabetes
Malik, F. S., & Taplin, C. E. (2014) · Pediatric Drugs · doi:10.1007/s40272-014-0064-6 · Cited by 109
“Continuous glucose monitoring (CGM) systems, which measure interstitial fluid glucose semicontinuously, have the potential to provide information on trends in the decline or rise of BGL that would not be identified in conventional monitoring; thus, they are being increasingly utilized in the overnight setting to avoid…”
BackgroundFavero, S. D., Place, J., Kropff, J., Messori, M., Keith-Hynes, P., VISENTIN, R., Monaro, M., Galasso, S., Boscari, F., Toffanin, C., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12440 · Cited by 95
REDONDO, M. J., Libman, I. M., Maahs, D. M., Lyons, S. K., Saraco, M., Reusch, J. E. B., Rodriguez, H., & DiMeglio, L. A. (2021) · Diabetes Care · doi:10.2337/dc20-1978 · Cited by 95
Cichosz, S. L., Frystyk, J., Hejlesen, O. K., Tarnow, L., & Fleischer, J. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814528838 · Cited by 88
“Ly et al and Bergenstal et al have shown the potential for CGM/insulin pump to reduce incidences of moderate and severe hypoglycemia.(22,23) We wanted to test the hypothesis that HRV patterns in combination with CGM data could be used as an improved method to real-time early detection of hypoglycemia.”
MethodClinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes
Slattery, D., & Choudhary, P. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0051 · Cited by 87
“Four SH were reported in the control group and none in the LGS group.(30) Danne et al.”
Management of Type 1 Diabetes in Older Adults
Dhaliwal, R., & Weinstock, R. S. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.1.9 · Cited by 99
Closed-Loop Artificial Pancreas Systems: Physiological Input to Enhance Next-Generation Devices
Kudva, Y. C., Carter, R. E., Cobelli, C., Basu, R., & Basu, A. (2014) · Diabetes Care · doi:10.2337/dc13-2066 · Cited by 93
Little, S. A., Speight, J., Leelarathna, L., Walkinshaw, E., Tan, H. K., Bowes, A., Lubina-Solomon, A., Chadwick, T. J., Stocken, D. D., Brennand, C., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2682 · Cited by 86
Heinemann, L., Fleming, G. A., Petrie, J. R., Holl, R. W., Bergenstal, R. M., & Peters, A. L. (2015) · Diabetologia · doi:10.1007/s00125-015-3513-z · Cited by 87
“In this way, basal insulin infusion is interrupted for 2 h if the glucose level reaches a pre-specified value and the patient does not react to the hypoglycaemia alert [3, 4].”
BackgroundSelf-citationTauschmann, M., Allen, J. M., Wilinska, M. E., Thabit, H., Acerini, C. L., Dunger, D. B., & Hovorka, R. (2016) · Diabetes Care · doi:10.2337/dc16-1094 · Cited by 83
Jacobs, P. G., Youssef, J. E., Castle, J. R., Bakhtiani, P. A., Branigan, D. L., Breen, M. E., Bauer, D., Preiser, N., Leonard, G., Stonex, T. M., et al. (2014) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2014.2323248 · Cited by 90
Management of Diabetes in the Elderly
Bansal, N., Dhaliwal, R., & Weinstock, R. S. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.11.008 · Cited by 90
Automated closed-loop control of diabetes: the artificial pancreas
Kovatchev, B. P. (2018) · Bioelectronic Medicine · doi:10.1186/s42234-018-0015-6 · Cited by 91
A Century of Diabetes Technology: Signals, Models, and Artificial Pancreas Control
Kovatchev, B. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.04.008 · Cited by 80
Puhr, S., Derdzinski, M., Welsh, J. B., Parker, A. S., Walker, T., & Price, D. A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0359 · Cited by 78
“23,24 The current data demonstrate that the incorporation of a predictive low glucose alert into a G6 CGM system further diminishes hypoglycemia exposure, significantly reducing hypoglycemia relative to a CGM system without the predictive alert, independent of threshold alert setting.”
BackgroundSelf-citationMoon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Psychological Reactions Associated With Continuous Glucose Monitoring in Youth
Patton, S. R., & Clements, M. A. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816638109 · Cited by 81
Closed-Loop System in the Management of Diabetes: Past, Present, and Future
Shah, V. N., Shoskes, A., Tawfik, B., & Garg, S. K. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0193 · Cited by 84
Self-citationNimri, R., Nir, J., & Phillip, M. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001097 · Cited by 94
Dual‐hormone artificial pancreas: benefits and limitations compared with single‐hormone systems
Peters, T. M., & Haidar, A. (2018) · Diabetic Medicine · doi:10.1111/dme.13581 · Cited by 84
Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement
Bartlett, S. T., Markmann, J. F., Johnson, P., Korsgren, O., Hering, B. J., Scharp, D. W., Kay, T. W. H., Bromberg, J. S., Odorico, J. S., Weir, G. C., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000001055 · Cited by 80
“hypoglycemia, showed significant reductions in hypoglycemia: automation to simulate pancreatic insulin response showed a 38% reduction in nocturnal hypoglycemia compared to CGM alone without increasing HbA1c.(207) In the second randomized control trial, LGS versus CSII showed a significant reduction in severe hypoglyc…”
MethodRiemsma, R., Corro Ramos, I., Birnie, R., Büyükkaramikli, N., Armstrong, N., Ryder, S., Duffy, S., Worthy, G., Al, M., Severens, J., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20170 · Cited by 73
Heller, S., White, D., Lee, E., Lawton, J., Pollard, D., Waugh, N., Amiel, S., Barnard, K., Beckwith, A., Brennan, A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21200 · Cited by 73
“The trial was sponsored by Medtronic, and Medtronic staff were involved in data analysis and editorial assistance.(74) The trial showed no difference in HbA1c after 3 months, perhaps not surprisingly because the baseline HbA1c was very good at 7.”
MethodJoseph, J. I. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820911919 · Cited by 81
Basics and use of continuous glucose monitoring (CGM) in diabetes therapy
Freckmann, G. (2020) · Journal of Laboratory Medicine · doi:10.1515/labmed-2019-0189 · Cited by 85
“Some of these pump systems already use a low glycemic suspend to stop basal rate for up to 2 h if glucose is low [11].”
BackgroundMachine Learning na Medicina: Revisão e Aplicabilidade
Paixao, G. M., Santos, B. C., de Araujo, R. M., Ribeiro, M. H., de Moraes, J. L., & Ribeiro, A. L. P. (2022) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20200596 · Cited by 100
Borot, S., Benhamou, P., Atlan, C., Bismuth, É., Bonnemaison, É., Catargi, B., Charpentier, G., Farret, A., Filhol, N., Franc, S., et al. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.10.009 · Cited by 79
“Stopping the basal rate for more than 2 h can expose patients to hyperglycaemic rebound [23], which is often slow and delayed.”
2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2023) · Current Topics in Diabetes · doi:10.5114/ctd/160061 · Cited by 85
Boscari, F., & Avogaro, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09635-3 · Cited by 80
“The first automated approach was dedicated to control hypoglycemia: the Low Glucose Suspend system (LGS) interrupts insulin infusion for a maximum of 2 h when a predetermined low glucose level is reached: this approach can reduce severe hypoglycemia, even if compared to SAP without LGS [89], especially in T1D at high…”
MethodCherñavvsky, D. R., DeBoer, M. D., Keith-Hynes, P., Mize, B., McElwee, M., Demartini, S., Dunsmore, S. F., Wakeman, C., Kovatchev, B. P., & Breton, M. D. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12230 · Cited by 68
“Commercially available systems are able to suspend insulin delivery in response to dropping blood glucose (BG) to prevent hypoglycemia (15).”
BackgroundReddy, N., Verma, N., & Dungan, K. M. (2020) · MDText.com, Inc. eBooks · Cited by 108
Glycaemic variability: The under‐recognized therapeutic target in type 1 diabetes care
Wilmot, E. G., Choudhary, P., Leelarathna, L., & Baxter, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13842 · Cited by 72
“delivery when the sensor glucose value reaches a predefined threshold.(76) By contrast, predictive low-glucose insulin suspension technol-”
BackgroundWood, A. J., O'Neal, D. N., Furler, J., & Ekinci, E. I. (2018) · Internal Medicine Journal · doi:10.1111/imj.13770 · Cited by 76
Dutta, T., Kudva, Y. C., Persson, X.-M. T., Schenck, L. A., Ford, G. C., Singh, R. J., Carter, R. E., & Nair, K. S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2640 · Cited by 66
Vigersky, R. A. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814565661 · Cited by 63
“Bergenstal and colleagues reported a significant reduction in rate and severity of hypoglycemia during a 3 months trial in adults using an LGTS system compared to those using SAP without an increase in A1c in either group.(53) There were important inclusion criteria for this study that inform us about who may benefit…”
MethodA Review of Safety and Design Requirements of the Artificial Pancreas
Blauw, H., Keith-Hynes, P., Koops, R., & DeVries, J. H. (2016) · Annals of Biomedical Engineering · doi:10.1007/s10439-016-1679-2 · Cited by 75
Improved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts
Abraham, S. B., Arunachalam, S., Zhong, A., Agrawal, P., Cohen, O., & McMahon, C. M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819859334 · Cited by 63
Forlenza, G. P., Buckingham, B. A., & Maahs, D. M. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.10.015 · Cited by 70
Rickels, M. R., Peleckis, A. J., DALTON-BAKES, C. V., Naji, J. R., Ran, N. A., Nguyen, H.-L., O’Brien, S., Chen, S., Lee, I., & Schutta, M. H. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01516 · Cited by 63
Petrovski, G., Al Khalaf, F., Campbell, J., Umer, F., Almajaly, D., Hamdan, M., & Hussain, K. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01607-4 · Cited by 56
Real‐world performance of the MiniMed™ 670G system in Europe
Da Silva, J., Bosi, E., Jendle, J., Arrieta, A., Castaneda, J., Grossman, B., Cordero, T. L., Shin, J., & Cohen, O. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14424 · Cited by 60
“This is in contrast to non-automated insulin delivery, where insulin therapy increasing TIR or reducing mean glucose and reducing HbA1c is often associated with increased hypoglycaemia.(17,18) Longitudinal analysis of real-world outcomes showed a rapid beneficial effect with Auto Mode initiation that was apparent as e…”
BackgroundClinical Implications of Accuracy Measurements of Continuous Glucose Sensors
Bailey, T. S. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0050 · Cited by 60
Thabit, H., & Hovorka, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1115013 · Cited by 58
“hypoglycaemic events during the run-in phase.[53] The mean area under the curve for nocturnal hypoglycaemic events was lower by 37.”
BackgroundModeling Transient Disconnections and Compression Artifacts of Continuous Glucose Sensors
Facchinetti, A., Favero, S. D., Sparacino, G., & Cobelli, C. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0250 · Cited by 63
“…(e.g., sensor-augmented pumps, in which the modulation of basal insulin dosage is based on actual and predicted glucose levels measured by the CGM sensor, 2,3 and artificial pancreas systems, where the insulin dosage is tuned by a closed-loop control algorithm on the basis of CGM readings 4,5 ).”
Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-8963 · Cited by 69
Routine use of continuous glucose monitoring in 10 501 people with diabetes mellitus
Battelino, T., Liabat, S., Veeze, H. J., Castañeda, J., Arrieta, A., & Cohen, O. (2015) · Diabetic Medicine · doi:10.1111/dme.12825 · Cited by 63
Sensor-Augmented Insulin Pumps and Hypoglycemia Prevention in Type 1 Diabetes
Steineck, I. I. K., Ranjan, A. G., Nørgaard, K., & Schmidt, S. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816672689 · Cited by 63
Nonadjunctive Use of Continuous Glucose Monitoring for Diabetes Treatment Decisions
Castle, J. R., & Jacobs, P. G. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816631569 · Cited by 56
“The MiniMed 530G insulin pump system and the Medtronic Veo insulin pump can suspend insulin if the sensor falls below a threshold and the user doesn’t respond to an alarm.(29) Likewise the Medtronic 640G insulin pump system provides a predictive low glucose suspend if the patient is not responding to alarms and the sy…”
MethodBequette, B. W., Cameron, F. M., Buckingham, B. A., Maahs, D. M., & Lum, J. W. (2018) · IEEE Control Systems · doi:10.1109/mcs.2017.2767119 · Cited by 57
“These systems are intended for use 24 h per day and include the 530G and 630G, both of which are threshold-based, LSGs without any predictive capabilities [6].”
BackgroundÇöpür, S., Onal, E. M., Afşar, B., Ortíz, A., van Raalte, D. H., Cherney, D. Z. I., Rossing, P. R., & Kanbay, M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107707 · Cited by 60
Renard, É., Joubert, M., Villard, O., Dreves, B., Reznik, Y., Farret, A., Place, J., Breton, M. D., & Kovatchev, B. P. (2023) · Diabetes Care · doi:10.2337/dc23-0685 · Cited by 64
Threshold Insulin-Pump Interruption to Reduce Hypoglycemia
Bergenstal, R. M., Welsh, J. B., & Shin, J. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1310365 · Cited by 56
Self-citationChamberlain, J. J., Doyle-Delgado, K., Peterson, L., & SKOLNIK, N. (2019) · Annals of Internal Medicine · doi:10.7326/m19-1638 · Cited by 60
Severe Hypoglycemia: Is It Still a Threat for Children and Adolescents With Type 1 Diabetes?
Urakami, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00609 · Cited by 59
Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study
Weiss, R., Garg, S. K., Bode, B. W., Bailey, T. S., Ahmann, A. J., Schultz, K. A., Welsh, J. B., Shin, J. J., & for the ASPIRE In-Home Study Group (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0306 · Cited by 56
“Secondary outcomes based on NH events were compared between groups, categorized by baseline A1C and DA1C.”
BackgroundMethodInfluentialSelf-citationEvaluation of a Predictive Low-Glucose Management System In-Clinic
Buckingham, B. A., Bailey, T. S., Christiansen, M., Garg, S., Weinzimer, S., Bode, B., Anderson, S. M., Brazg, R., Ly, T. T., & Kaufman, F. R. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0319 · Cited by 52
“7,8 As demonstrated in several in-clinic and at-home studies, algorithms that suspend insulin delivery in anticipation of hypoglycemia prevent many hypoglycemic episodes that might have otherwise occurred.”
Self-citationChoudhary, P., & Amiel, S. A. (2018) · Diabetologia · doi:10.1007/s00125-018-4566-6 · Cited by 52
“One RCT, which compared a device providing automated suspension of insulin delivery in response to sensor hypoglycaemia vs SAP without this feature, demonstrated a 38% reduction in the number of nocturnal hypoglycaemic events [40].”
Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases
ALMURASHI, A. M., Rodriguez, E., & Garg, S. K. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-022-00348-3 · Cited by 66
Self-citationVettoretti, M., & Facchinetti, A. (2019) · BioMedical Engineering OnLine · doi:10.1186/s12938-019-0658-x · Cited by 56
Ahmadi, S. S., Westman, K., Pivodic, A., Ólafsdóttir, A. F., Dahlqvist, S., Hirsch, I. B., Hellman, J., Ekelund, M., Heise, T., Polonsky, W. H., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2606 · Cited by 55
Birkebæk, N., Drivvoll, A., Aakesson, K., Bjarnason, R. G., Johansen, A., Samuelsson, U., Skrivarhaug, T., Þórsson, Á. V., & Svensson, J. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000377 · Cited by 53
Hypoglycemia in diabetes: The dark side of diabetes treatment. A patient‐centered review
Johnson‐Rabbett, B., & Seaquist, E. R. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12933 · Cited by 55
“Both studies had a randomized cross-over design, with 501 patients enrolled in SWITCH-1 and 721 patients enrolled in SWITCH-2.”
BackgroundResultInfluentialChristiansen, S. C., Fougner, A. L., Stavdahl, Ø., Kölle, K., Ellingsen, R., & Carlsen, S. M. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0263-6 · Cited by 55
“In recent years, CGM technology has been incorporated into CSII technology, enabling insulin delivery to be suspended during hypoglycemic episodes that occur during unawareness or sleep [15, 16].”
BackgroundGrunberger, G., Handelsman, Y., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Haas, R. A., Roberts, V. L., & Umpierrez, G. E. (2018) · Endocrine Practice · doi:10.4158/ps-2017-0155 · Cited by 49
Advances in Type 1 Diabetes Technology Over the Last Decade
Zimmerman, C. F., Albanese-O’Neill, A., & Haller, M. J. (2019) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2019.15.2.70 · Cited by 53
“It also introduced the threshold suspend function, which used SmartGuard™ technology to suspend basal insulin for up to 2 hours if the patient did not respond to a low glucose alert.11 This feature was shown to reduce night-time hypoglycaemia without increasing HbA1c.33 Medtronic has discontinued production of these l…”
BackgroundClosed-loop insulin delivery: update on the state of the field and emerging technologies
Ware, J., & Hovorka, R. (2022) · Expert Review of Medical Devices · doi:10.1080/17434440.2022.2142556 · Cited by 47
Wearable systems and mobile applications for diabetes disease management
Georga, E. I., Protopappas, V. C., Bellos, C. V., & Fotiadis, D. I. (2014) · Health and Technology · doi:10.1007/s12553-014-0082-y · Cited by 51
“Very encouraging is that SAP with the threshold-suspend feature has been recently shown to significantly reduce nocturnal and overall hypoglycemia without any apparent change in HbA1c compared to SAP alone [42, 43].”
ResultDiabetes Technology Use in Adults with Type 1 and Type 2 Diabetes
Kravarusic, J., & Aleppo, G. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.006 · Cited by 42
Metadata
- Authors
- Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R.
- Affiliations
- Park Nicollet Health Services (US)
- Mills Peninsula Health Services (US)
- University of Colorado Denver (US)
- Atlanta Diabetes Associates (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 224-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102877966
- Cited by
- 652
- References
- 21
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 18 · 2023: 36 · 2022: 30 · 2021: 41 · 2020: 39 · 2019: 62 · 2018: 75 · 2017: 80 · 2016: 82 · 2015: 74 · 2014: 73 · 2013: 17
- FWCI
- 64.50
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Repositorio Institucional (Pontificia Universidad Javeriana) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- sensor-augmented pump, insulin pump therapy, nocturnal hypoglycemia, type 1 diabetes, HbA1c, hypoglycemia prevention, continuous glucose monitoring, glycemic control, hypoglycemic events, hypoglycemia severity, hypoglycemia duration
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Area Under Curve, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.